BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

As Arcus becomes the second company to report clinical data for a CD73 inhibitor in pancreatic cancer behind front-runner AstraZeneca, at least six more teams have early-stage clinical programs targeting the immuno-metabolism modulating receptor. An...
BioCentury | Jan 15, 2021
Finance

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

...Capital.TARGETSCETP – Cholesteryl ester transfer protein Paul Bonanos Obicetrapib (TA-8995, AMG 899) NewAmsterdam Pharma B.V. Cholesteryl ester transfer protein (CETP) Endocrine/Metabolic bee2021...
BioCentury | Jan 13, 2021
Management Tracks

Spark vet High joins AskBio; plus Rotthier to lead Sanofi API unit and moves at Immunovant, Innocoll

...of Akebia Therapeutics Inc. (NASDAQ:AKBA) and, before that, VP of men’s and women’s health and metabolic...
BioCentury | Jan 8, 2021
Management Tracks

Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute

...Craig Tooman as CFO. Tooman, who succeeds Rob Quinn, was CFO and COO at Vyome Therapeutics Inc.Metabolic...
BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...value of $562 million. The divested portfolio comprises mostly European products in therapeutic categories such as cardiovascular-metabolic...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...new indications spanned neurology, musculoskeletal diseases and metabolic...
BioCentury | Dec 31, 2020
Distillery Therapeutics

Combining cholesterol metabolism inhibition with T cell therapy for glioblastoma, melanoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; melanoma Tethering T cell therapies to an inhibitor of the cholesterol metabolism enzyme SOAT could enhance the cell therapy’s efficacy against glioblastoma and melanoma. The T cells were engineered...
BioCentury | Dec 31, 2020
Distillery Therapeutics

SIRT5 overexpression could rescue mitochondrial disease induced by SUCLA2 mutations

...San Francisco University of Helsinki Buck Institute for Research on Aging Succinate-CoA ligase ADP-forming beta subunit (SUCLA2) Sirtuin 5 (SIRT5) Endocrine/Metabolic Mitochondrial...
BioCentury | Dec 31, 2020
Finance

Dec. 30 Quick Takes: Transcenta leads year-end crop of China venture rounds

...cancer and genetic diseases and develops algorithms for drug design and repurposing.Eccogene raises over $15M Metabolic...
BioCentury | Dec 21, 2020
Deals

Agios to exit oncology, reward investors via Servier deal as lead anemia program nears submission

...Using the same blueprint as it did for the cancer drugs, Agios began studying rare metabolic...
Items per page:
1 - 10 of 27680
BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

As Arcus becomes the second company to report clinical data for a CD73 inhibitor in pancreatic cancer behind front-runner AstraZeneca, at least six more teams have early-stage clinical programs targeting the immuno-metabolism modulating receptor. An...
BioCentury | Jan 15, 2021
Finance

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

...Capital.TARGETSCETP – Cholesteryl ester transfer protein Paul Bonanos Obicetrapib (TA-8995, AMG 899) NewAmsterdam Pharma B.V. Cholesteryl ester transfer protein (CETP) Endocrine/Metabolic bee2021...
BioCentury | Jan 13, 2021
Management Tracks

Spark vet High joins AskBio; plus Rotthier to lead Sanofi API unit and moves at Immunovant, Innocoll

...of Akebia Therapeutics Inc. (NASDAQ:AKBA) and, before that, VP of men’s and women’s health and metabolic...
BioCentury | Jan 8, 2021
Management Tracks

Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute

...Craig Tooman as CFO. Tooman, who succeeds Rob Quinn, was CFO and COO at Vyome Therapeutics Inc.Metabolic...
BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...value of $562 million. The divested portfolio comprises mostly European products in therapeutic categories such as cardiovascular-metabolic...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...new indications spanned neurology, musculoskeletal diseases and metabolic...
BioCentury | Dec 31, 2020
Distillery Therapeutics

Combining cholesterol metabolism inhibition with T cell therapy for glioblastoma, melanoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; melanoma Tethering T cell therapies to an inhibitor of the cholesterol metabolism enzyme SOAT could enhance the cell therapy’s efficacy against glioblastoma and melanoma. The T cells were engineered...
BioCentury | Dec 31, 2020
Distillery Therapeutics

SIRT5 overexpression could rescue mitochondrial disease induced by SUCLA2 mutations

...San Francisco University of Helsinki Buck Institute for Research on Aging Succinate-CoA ligase ADP-forming beta subunit (SUCLA2) Sirtuin 5 (SIRT5) Endocrine/Metabolic Mitochondrial...
BioCentury | Dec 31, 2020
Finance

Dec. 30 Quick Takes: Transcenta leads year-end crop of China venture rounds

...cancer and genetic diseases and develops algorithms for drug design and repurposing.Eccogene raises over $15M Metabolic...
BioCentury | Dec 21, 2020
Deals

Agios to exit oncology, reward investors via Servier deal as lead anemia program nears submission

...Using the same blueprint as it did for the cancer drugs, Agios began studying rare metabolic...
Items per page:
1 - 10 of 27680